



# MATERIAL SAFETY DATA SHEET

Revision date: 15-Dec-2006

Version: 1.1

Page 1 of 6

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

**Pfizer Inc**  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-212-573-2222

**Pfizer Ltd**  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

Emergency telephone number:  
CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:  
ChemSafe (24 hours): +44 (0)208 762 8322

### Material Name: Prazepam Capsules

**Trade Name:** Prasepine  
**Chemical Family:** Mixture  
**Intended Use:** Pharmaceutical product used as Antidepressant/antianxiety.

## 2. COMPOSITION/INFORMATION ON INGREDIENTS

### Hazardous

Ingredient	CAS Number	EU EINECS List	%
Magnesium stearate	557-04-0	209-150-3	*
Prazepam	2955-38-6	220-975-8	2

Ingredient	CAS Number	EU EINECS List	%
Lactose	63-42-3	200-559-2	*

**Additional Information:** \* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

## 3. HAZARDS IDENTIFICATION

**Appearance:** Capsules  
**Signal Word:** WARNING

**Statement of Hazard:** Suspected of damaging fertility.  
May cause central nervous system effects

**Additional Hazard Information:**  
**Short Term:** Not acutely toxic (based on components) .  
**Long Term:** Repeat-dose studies in animals have shown a potential to cause adverse effects on liver, male reproductive system.

**Known Clinical Effects:** Therapeutic use of this substance has resulted in weakness, dizziness, drowsiness, ataxia, confusion, tremors, headache, and gastrointestinal disturbances. This material has been shown to be secreted in low concentrations in human breast milk. The following effects are based on a chemically-related material: symptoms of dependence/withdrawal, insomnia, amnesia, agitation, nightmares, hallucinations.

**EU Indication of danger:** Not classified

## MATERIAL SAFETY DATA SHEET

Material Name: Prazepam Capsules  
Revision date: 15-Dec-2006

Page 2 of 6  
Version: 1.1

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 4. FIRST AID MEASURES

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:** May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

**Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

**Fire / Explosion Hazards:** Not determined

### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Measures for Environmental Protections:** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

# MATERIAL SAFETY DATA SHEET

Material Name: Prazepam Capsules  
Revision date: 15-Dec-2006

Page 3 of 6  
Version: 1.1

**General Handling:** Avoid generating airborne dust. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes.

**Storage Conditions:** Store at controlled room temperature. Protect from light.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Magnesium stearate**  
ACGIH Threshold Limit Value (TWA) = 10 mg/m<sup>3</sup> TWA except stearates of toxic metals  
Australia TWA = 10 mg/m<sup>3</sup> TWA

**Prazepam**  
Pfizer OEL TWA-8 Hr: 0.02 mg/m<sup>3</sup>  
The exposure limit(s) listed for solid components are only relevant if dust may be generated.

**Analytical Method:** Analytical method available for Prazepam. Contact Pfizer Inc for further information.

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.

### Personal Protective Equipment:

**Hands:** Not required for the normal use of this product. Wear protective gloves when working with large quantities.

**Eyes:** Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

**Skin:** Not required for the normal use of this product. Wear protective clothing when working with large quantities.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

## 9. PHYSICAL AND CHEMICAL PROPERTIES:

**Physical State:** Capsule  
**Color:** No data available.  
**Molecular Formula:** Mixture  
**Molecular Weight:** Mixture

## 10. STABILITY AND REACTIVITY

**Stability:** Stable under normal conditions of use.  
**Conditions to Avoid:** Light  
**Incompatible Materials:** No data available

## 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

### Acute Toxicity: (Species, Route, End Point, Dose)

**Prazepam**  
Mouse Oral LD50 2.3 g/kg  
Rat Oral LD50 >4 g/kg  
Rat IP LD50 >2 g/kg

## MATERIAL SAFETY DATA SHEET

Material Name: Prazepam Capsules  
Revision date: 15-Dec-2006

Page 4 of 6  
Version: 1.1

Mouse IP LD50 1 g/kg

### Lactose

Rat Oral LD50 > 10 g/kg

### Magnesium stearate

Rat Oral LD50 > 2000 mg/kg

Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Prazepam

35 Day(s) Rat Oral 35 mg/kg LOAEL Liver, Male reproductive system

12 Week(s) Dog No route specified 13.5 mg/kg/day NOAEL Liver

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

#### Prazepam

Reproductive & Fertility Mouse Oral 0.02 % LOAEL Reproductive toxicity, Fetotoxicity

Reproductive & Fertility Rat No route specified 80 mg/kg LOAEL Reproductive toxicity, Fetotoxicity

Embryo / Fetal Development Rat Oral 250 mg/kg NOAEL Negative

Embryo / Fetal Development Rabbit No route specified 80 times human dose NOAEL No effects at maximum dose

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

**Genetic Toxicity Comments:** Genetic toxicity tests were negative

### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Prazepam

2 Year(s) Rat Oral, in feed Not carcinogenic

2 Year(s) Mouse Oral, in feed Not carcinogenic

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

#### Prazepam

**IARC:** Group 3

## 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Releases to the environment should be avoided. Environmental properties have not been thoroughly investigated.

## 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

# MATERIAL SAFETY DATA SHEET

Material Name: Prazepam Capsules  
Revision date: 15-Dec-2006

Page 5 of 6  
Version: 1.1

## 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

EU Indication of danger: Not classified

### OSHA Label:

WARNING

Suspected of damaging fertility.

May cause central nervous system effects

### Canada - WHMIS: Classifications

#### WHMIS hazard class:

D2a - very toxic materials



#### Lactose

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	200-559-2

#### Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	209-150-3

#### Prazepam

Drug Enforcement Administration:	Schedule IV
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS List	220-975-8

Additional Information: US DEA Schedule IV substance

## 16. OTHER INFORMATION

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information.

## MATERIAL SAFETY DATA SHEET

Material Name: Prazepam Capsules

Revision date: 15-Dec-2006

Page 6 of 6

Version: 1.1

---

**Prepared by:**

Toxicology and Hazard Communication  
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

**End of Safety Data Sheet**